PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 35058313-4 2022 RESULTS: Glucose-derived glycation products fructose-lysine (FL), glucosepane (GSPN) and carboxymethyl-lysine (CML) decreased with intensive glycemic control at both TP1 and TP2 (p<0.0001) but were similar at TP3, and correlated with hemoglobin A1c (HbA1c). Glucose 9-16 transition protein 1 Homo sapiens 166-169 28732858-5 2017 STP-1 had a major molecular weight of 190.4kDa, and comprised of arabinose, galactose, glucose, xylose, mannose, galacturonic acid, and glucuronic acid with molar percentages of 1.94, 30.7, 4.54, 23.2, 17.6, 8.11, and 13.9%, respectively. Glucose 87-94 transition protein 1 Homo sapiens 0-5 28732858-6 2017 In addition, STP-1 showed strong antioxidant and alpha-glucosidase inhibitory activities, and could improve the glucose uptake in insulin-resistant HepG2 cells, suggesting that STP-1 can be exploited as a promising natural antioxidant and hypoglycemic agent. Glucose 112-119 transition protein 1 Homo sapiens 13-18 28732858-6 2017 In addition, STP-1 showed strong antioxidant and alpha-glucosidase inhibitory activities, and could improve the glucose uptake in insulin-resistant HepG2 cells, suggesting that STP-1 can be exploited as a promising natural antioxidant and hypoglycemic agent. Glucose 112-119 transition protein 1 Homo sapiens 177-182 34359730-1 2021 We aimed to investigate, whether 18F-2-fluoro-2-desoxy-D-glucose positron emission tomography/computed tomography (FDG-PET/CT) scans performed at baseline (time point 0; TP 0) and three months after initiation of immunotherapy (time point 1; TP 1) can be used on a metastasis- and patient-level to predict the response to immune-checkpoint inhibition using FDG-PET/CT six months after treatment start (time point 2; TP 2) in metastatic melanoma patients. Glucose 57-64 transition protein 1 Homo sapiens 242-246